Press Releases

March 27, 2017
Tarveda to Present PEN-221 Data in Small Cell Lung Cancer Models at 2017 American Association for Cancer Research Annual Meeting

March 1, 2017
Tarveda Announces Presentation and Panel Participation at Upcoming Conferences

February 9, 2017
Tarveda to Present at the BIO CEO & Investor Conference February 14

February 2, 2017
Tarveda Therapeutics Raises $30 Million in Series D Financing to Advance Pentarin Miniaturized Drug Conjugates

January 5, 2017
Tarveda Therapeutics Provides Year-End Update and Outlines Milestones for 2017

January 5, 2017
Tarveda to Present at Biotech Showcase January 9, 2017

January 4, 2017
Tarveda Therapeutics Announces Phase 1/2a Clinical Trial of PEN-221 Underway in Patients with Neuroendocrine Tumors and Small Cell Lung Cancer

November 22, 2016
Tarveda to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

September 29, 2016
Tarveda to Present at North American Neuroendocrine Tumor Society (NANETS) Symposium

September 19, 2016
Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform

February 29, 2016
Tarveda Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

January 27, 2016
Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., as Chief Medical Officer

January 27, 2016
Tarveda Therapeutics Emerges and Secures $38 Million in Series C Financing led by Novo A/S and NEA

April 21, 2015
Blend Therapeutics Presents Preclinical Data for Lead Pentarin™ Program, BTP-277 (now PEN-221), Demonstrating Specific and Potent Tumor Cell Targeting for Small-Cell Lung Cancer

April 13, 2015
Blend Therapeutics Appoints Drew Fromkin as President and Chief Executive Officer

January 7, 2015
Blend Therapeutics Appoints Distinguished Physician Scientist, Dennis Ausiello, MD, to Board of Directors